Aldeyra Therapeutics (ALDX) Return on Capital Employed (2014 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Return on Capital Employed came in at 63.15% in Q1 2026, up 911.0% YoY from 6.25% in Q1 2025, and up 15.61% on a QoQ basis from 74.84% in Q4 2025.
Aldeyra Therapeutics (ALDX) Return on Capital Employed (2014 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 13 years of Return on Capital Employed data on file, last reported at 63.15% in Q1 2026.
- Quarterly Return on Capital Employed rose 911.0% year-over-year to 63.15% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 63.15% (up 911.0% YoY) and the FY2025 annual result came in at 58.27%, down 253.0% from the prior year.
- Return on Capital Employed rose to 63.15% in Q1 2026, from 74.84% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 28.74% in Q1 2024 to a low of 89.53% in Q2 2025.
- A 5-year average of 50.27% and a median of 39.69% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 1095 bps — and 2025, when it tumbled 4894 bps.
- Tracing ALDX's Return on Capital Employed over 5 years: stood at 36.84% in 2022, then increased by 7 bps to 34.09% in 2023, then slumped by 91 bps to 65.09% in 2024, then slipped by 15 bps to 74.84% in 2025, then rose by 16 bps to 63.15% in 2026.
- The last three Return on Capital Employed figures came in at 63.15% (Q1 2026), 74.84% (Q4 2025), and 85.4% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | -50.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.82% |
| Mar 31, 2026 | -63.15% |
| Dec 31, 2025 | -74.84% |
| Sep 30, 2025 | -85.40% |
| Jun 30, 2025 | -89.53% |
| Mar 31, 2025 | -72.27% |
| Dec 31, 2024 | -65.09% |
| Sep 30, 2024 | -47.49% |
| Jun 30, 2024 | -40.58% |
| Mar 31, 2024 | -28.74% |
| Dec 31, 2023 | -34.09% |
| Sep 30, 2023 | -38.81% |
| Jun 30, 2023 | -38.02% |
| Mar 31, 2023 | -39.69% |
| Dec 31, 2022 | -36.84% |
| Sep 30, 2022 | -37.62% |
| Jun 30, 2022 | -33.25% |
| Mar 31, 2022 | -29.25% |
| Dec 31, 2021 | -24.61% |
| Sep 30, 2021 | -21.72% |